Nvidia delays 10-Q filing over Huang investigation disclosures
Nvidia said it planned to file its quarterly 10-Q with the SEC “in the coming weeks,” rather than on the same day it reported earnings as usual. According to UBS analyst Timothy Arcuri, Nvidia management said the delay was related to its ongoing investigation into Jensen Huang and whether the filing needed to include additional information or risk factors. The report did not specify the final filing date or what additional disclosures, if any, would be included.
The unusual timing means investors will wait longer for the detailed filing that includes disclosures about legal proceedings and risk factors. The filing’s contents remain uncertain, but it is expected to receive scrutiny given the ongoing investigation and Nvidia’s legal troubles.
During Nvidia’s quarterly call on Tuesday, CFO-turned-interim-CEO Colette Kress dropped this little oddity: She said Nvidia wouldn’t be immediately filing its quarterly results report, known as a 10-Q, with the SEC. “We plan to file our 10-Q in the coming weeks.” And she offered no reason why.
The delay was widely noticed. Among the many comments on X about it, economic and investment analyst Edward Dowd called it a “red flag.” Nvidia has typically filed the 10-Q the same day it reports results.
The 10-Q offers far more detail about a company’s operations than an earnings press release, including sections that disclose “legal proceedings,” which include lawsuits that could affect the company; and “risk factors,” which cover other potentially business-impairing items.
The announcement of the delay was so unusual that UBS analyst Timothy Arcuri asked about it after the public earnings call. Nvidia told him the delay was related to whether the company would need to disclose additional information about its ongoing investigation into Huang in the 10-Q.
“The company announced that the 10-Q will be filed ‘in the coming weeks’ – later than usual. When queried on our callback, management indicated this was related to the ongoing investigation and whether any additional risk factors would need to be added to the filing,” Arcuri wrote in his research note. (Arcuri still rates the stock a “buy” by the way, although he did lower his price target to $220 from $240. The stock is now trading around $150).